Affluent Medical Targets 2026 Market Entry
Company Announcements

Affluent Medical Targets 2026 Market Entry

Affluent Medical SA (FR:AFME) has released an update.

Affluent Medical, a French medtech firm, has detailed its share capital and voting rights while outlining its goals to lead in structural heart diseases and urinary incontinence treatments. The company, which is developing innovative, minimally invasive implants, plans to market its products by 2026 contingent on successful clinical trials and funding. The latest share count stands at 39,348,021 with 55,586,576 theoretical voting rights and 55,412,507 exercisable voting rights.

For further insights into FR:AFME stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskAffluent Medical SA Gears Up for Scientific Showcases
TipRanks European Auto-Generated NewsdeskAffluent Medical SA Reports Clinical and Financial Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App